Follow here to receive email alerts.
Bellicum Pharmaceuticals, Inc – Bellicum Pharmaceuticals, Inc. Sponsored Research Agreement No. 2 (August 8th, 2016) THIS SPONSORED RESEARCH AGREEMENT (the "Agreement") is entered into and made and effective as of May 20, 2016 ("Effective Date") by and between BELLICUM PHARMACEUTICALS, INC., with offices at 2130 West Holcombe Boulevard, Suite 800, Houston, Texas 77030, United States of America ("Sponsor"), and ACADEMISCH ZIEKENHUIS LEIDEN, also acting under the name Leiden University Medical Centre, with offices at Albinusdreef 2, 2333 ZA Leiden, The Netherlands ("Leiden"). Sponsor and Leiden are referred to herein collectively as the "Parties" or individually as a "Party."
THIS SPONSORED RESEARCH AGREEMENT (the "Agreement") is entered into and made and effective as of May 20, 2016 ("Effective Date") by and between BELLICUM PHARMACEUTICALS, INC., with offices at 2130 West Holcombe Boulevard, Suite 800, Houston, Texas 77030, United States of America ("Sponsor"), and ACADEMISCH ZIEKENHUIS LEIDEN, also acting under the name Leiden University Medical Centre, with offices at Albinusdreef 2, 2333 ZA Leiden, The Netherlands ("Leiden"). Sponsor and Leiden are referred to herein collectively as the "Parties" or individually as a "Party."